hrp0092p3-293 | Late Breaking Abstracts | ESPE2019

Clinical Evolution of a Patient with Isolated Growth Hormone Deficiency Type IA Treated with rIGF1 for 5 Years After The Development of GH-antibodies

Feliu Rovira Albert , Latorre Martinez Esther , Porcar Cardona Ines , Escribano Subias Joaquin

Introduction: Isolated growth hormone deficiency (IGHD) type IA causes a severe growth retardation. Their initial good response to exogenous GH is hampered by the development of anti-GH-antibodies leading to treat with IGF1 as the only therapeutic option. Here we present the evolution of a patient with IGHD type IA treated with IGF1r for more than 5 years.Description of the caseWe present a 5-year-...

hrp0095p1-397 | Thyroid | ESPE2022

Molecular Diagnosis of Non-Autoinmune Subclinical Hypothyroidism in Paediatrics

Gonzalez-Llorens Nuria , Antolin Mate Maria , Clemente Leon Maria , Campos Martorell Ariadna , Mogas Viñals Eduard , Soler Colomer Laura , Tomasini Rosangela , Gonzalez-Morla Judith , Murillo Valles Marta , Aguilar Riera Cristina , Casano Sancho Paula , Bosch Muñoz Jordi , Escuer Morell Mercè , Ortigosa Gomez Sandra , Hernandez-Herrero Maria , Feliu Rovira Albert , Camats-Tarruella Nuria , Baz-Redon Noelia , Fernandez-Cancio Monica , Yeste Fernandez Diego

Introduction: Subclinical hypothyroidism (SH) is a biochemical condition characterized by serum levels of TSH above the reference range upper limit (4,5μUI/mL), with normal concentrations of thyroid hormones. In cases of non-autoimmune subclinical hypothyroidism (NASHT), genetic defects have been described and can determine disorders in the biosynthesis process of thyroid hormones, such as heterozygous mutations in the TSH receptor gene (TSHR) and ...

hrp0084p2-429 | GH & IGF | ESPE2015

Effectiveness of Recombinant IGF1 Treatment in a Patient with Isolated GH IA Deficit Producer of Anti-GH Antibodies

Porcar Ines , Oriola Josep , Kratzsch Jurgen , Escribano Joaquin , Feliu Albert

Background: GH deficiency type IA represents the most serious form of isolated deficit GH (IDGH). It’s transmitted as an autosomal recessive pattern and in most cases there is a homozygous deletion of the GH1 gene. Good initial response to treatment is characteristic, although often could appear antibodies against recombinant GH.Case presentation: We report a case of a 5-year-old Pakistanist boy evaluated for severe growth failure (heigh <8.07 <...

hrp0092pl7 | Pituitary Gigantism - An Update | ESPE2019

Pituitary Gigantism – an Update

Beckers Albert

Pituitary gigantism is a rare disorder caused by excess of GH/IGF-1 due to GH-secreting lesions, that occurs before epiphyseal closure leading to increased linear growth. These cases have more aggressive features of pituitary disease than sporadic acromegaly, including a younger age at disease onset and larger tumor size, and they can be challenging to treat. Over the past two decades several molecular defects that cause GH-secreting pituitary adenomas have been identified, in...

hrp0082p1-d3-127 | Fat Metabolism &amp; Obesity (2) | ESPE2014

Infancy Lipidomic Analyses and Associations with Early Nutrition and Growth

Prentice Philippa , Koulman Albert , Matthews Lee , Acerini Carlo , Ong Ken , Dunger David

Background: Links between early life exposures and long-term health outcomes may in part be due to nutritional programming, and suggested benefits of breast feeding during infancy include reduced risk of obesity and metabolic disease. Mechanisms remain unexplained but potential differences in lipid exposures during infancy may be involved.Objective and hypotheses: To explore the effects of breast- or formula-feeding on lipidomic profiles we used recently...

hrp0097p1-518 | Growth and Syndromes | ESPE2023

Outcomes of growth hormone treatment in children with Prader Willi Syndrome over a 30-year period at the Children’s Hospital at Westmead, New South Wales Australia

Gamage Dilhara , Chan Albert , Maguire Ann , Srinivasan Shubha , Ambler Geoffrey , Hi Cho Yoon

Background: Prader-Willi syndrome (PWS) is a rare genetic obesity syndrome associated with relative growth hormone deficiency. Scoliosis is a known association of both PWS and growth hormone therapy (GH), although its role in causation remains uncertain. In the literature, short-term and long-term data revealed no adverse effects of GH on scoliosis. As the metabolic and clinical benefit of growth hormone therapy is established in the management of PWS, it is d...

hrp0086p1-p688 | Endocrinology and Multisystemic Diseases P1 | ESPE2016

Thyrotoxicosis, Nephrogenic Syndrome of Inappropriate Antidiuresis, Tall Stature and Mental Retardation Caused by a Novel GNAS Gain of Function Mutation

Houang Muriel , Kottler Marie-Laure , Bensman Albert , Haymann Jean-Philippe , Richard Nicolas , Dunand Olivier , Bastepe Murate , Silve Caroline , Coudray Nathalie , Netchine Irene , Linglart Agnes

Background: Nephrogenic syndrome of inappropriate antidiuresis (NSIAD) is a very rare clinical condition. Patients suffer from hyponatremia, hypo-osmolality with inappropriately elevated urinary osmolality and undetectable AVP levels. Activating mutations of AVPR2, the vasopressin receptor type 2 (V2R), induce a prolonged signaling of the intracellular cAMP/PKA pathway and cause NSIAD in patients.Objective and hypotheses: To describe a new phenotype in a...

hrp0094p1-33 | Fat, Metabolism and Obesity A | ESPE2021

Metabolomics in early life and the association with body composition at age 2 years

van Beijsterveldt Inge , Snowden Stuart , Myers Pernille Neve , Fluiter Kirsten de , Brix Susanne , Ong Ken , Dunger David , Hokken-Koelega Anita , Koulman Albert ,

Background and Objectives: Early life might be a critical window for adiposity programming later in life. Metabolic profile in early life may reflect this programming and correlate with later life adiposity. We investigated if metabolic profile at 3 months of age is predictive for body composition at age 2 years and if there are differences between boys and girls and between infant feeding types.Methods: In 318 healthy t...

hrp0084p1-127 | Thyroid | ESPE2015

Transient vs Permanent Congenital Hypothyroidism: The Use of Baseline Characteristics and Long-Term Data Can Help Formulate a Practical Prognostic Algorithm

Giogli Vassiliki , Kanaka-Gantenbein Christina , Chouliaras George , Arditi Jessica-Debora , Gika Anna , Iliadi Alexandra , Platis Dimitris , Kyritsi Eleni Magdalini , Karkalousos Petros , Karikas George-Albert , Mengreli Chrysanthi , Chrousos George , Girginoudis Panagiotis , Voutetakis Antonis

Background: Implementation of neonatal screening programs for congenital hypothyroidism (CH) has reduced related nosologies and has eradicated CH-associated mental impairment. With the decrease of the TSH cut-off limits employed to avoid false negative results, milder cases of CH are diagnosed. Obviously, in a number of patients, especially among milder CH cases, thyroid dysfunction is transient. The diagnosis of transient vs. permanent CH is established in time. No specific p...

hrp0095p1-4 | Adrenals and HPA Axis | ESPE2022

Glucocorticoid-induced adrenal insufficiency: morning plasma cortisol values safely assess recovery of the HPA axis in pediatrics

Laulhé Margaux , Dumaine Cécile , Chevenne Didier , Leye Fallou , Faye Albert , Dozières Blandine , Strullu Marion , Viala Jérôme , Hogan Julien , Houdouin Véronique , Léger Juliane , Simon Dominique , Claude Carel Jean , Storey Caroline , Guilmin-Crépon Sophie , Martinerie Laetitia

Background and Objectives: Chronic administration of synthetic glucocorticoids affects 1% of the world population and is responsible for secondary adrenal insufficiency for 40% of the patients. In pediatrics, glucocorticoid-induced adrenal insufficiency (GI-AI) diagnosis is based on the Low Dose Synacthen Test (LD-SST). Screening for glucocorticoid-induced adrenal insufficiency implies medical and economical costs due to the necessity of an intravenous line an...